In a considerable development, biotech player Noxopharm (ASX:NOX) has released details of the radiographic review of its DARRT-1 clinical study. The Company reported that the review demonstrates a significant benefit from a combination of low-dose radiotherapy and Veyonda®.
Additionally, the Company highlighted:
- Review providing further evidence of Veyonda®’s anti-cancer effect in patients with end-stage prostate cancer.
- 4/15 patients witnessed an abscopal response following DARRT, which is a remarkable result.
- In Company’s knowledge, this is first time that anyone has been able to attain a meaningful abscopal response rate in prostate cancer.
Post the key update, NOX stock inched higher by ~2.4 per cent, trading at $0.210 as at 12:07 PM AEST on 30th April 2020.